DHR · 10-Q · 2026Q2 · Full report
Revenue Performance and Mix
DANAHER CORP /DE/ · 2026-07-21 · Importance 49 · Surprise 32 · No source text
Second-quarter 2026 revenue increased 5.5% year over year to $6.265 billion, while core sales increased 3.0% and core sales excluding respiratory testing increased 4.5%. Six-month revenue increased 4.5% to $12.216 billion, with core sales up 2.0% and core sales excluding respiratory testing up 4.0%. Second-quarter segment sales were $2.466 billion for Diagnostics, $1.920 billion for Biotechnology and $1.879 billion for Life Sciences, representing year-over-year growth of 7.0%, 4.0% and 5.5%, respectively. Diagnostics growth reflected the Masimo acquisition and higher clinical diagnostics demand, while lower respiratory-testing demand reduced reported core growth; Biotechnology benefited from consumables and bioprocessing demand, and Life Sciences was led by filtration products and high-growth markets.
Key facts
- Total sales for the three-month period ended June 26, 2026 were $6,265 million and for the comparable period in 2025 were $5,936 million. source
- Total sales for the six-month period ended June 26, 2026 were $12,216 million and for the comparable period in 2025 were $11,677 million. source
- The Company’s net earnings for the three-month period ended June 26, 2026 totaled $870 million, or $1.23 per diluted common share. source
- The Company’s net earnings for the six-month period ended June 26, 2026 totaled approximately $1.9 billion, or $2.68 per diluted common share. source
- During the second quarter of 2026, the Company’s overall revenues increased 5.5% compared to the comparable period of 2025. source
- Core sales excluding respiratory testing increased 4.5% during the second quarter of 2026 compared to the comparable period of 2025. source
- For the six-month period ended June 26, 2026, the Company’s overall revenues increased 4.5% compared to the comparable period of 2025. source
- Core sales excluding respiratory testing increased 4.0% during the six-month period ended June 26, 2026 compared to the comparable period of 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +8.6% | Total sales for the six-month period ended June 26, 2026 were $12,216 million and for the comparable period in 2025 were $11,677 million. |
| revenue | positive | realized | +5.3% | Total sales for the three-month period ended June 26, 2026 were $6,265 million and for the comparable period in 2025 were $5,936 million. |
| net_income | positive | realized | — | The Company’s net earnings for the three-month period ended June 26, 2026 totaled $870 million, or $1.23 per diluted common share. |
| net_income | positive | realized | — | The Company’s net earnings for the six-month period ended June 26, 2026 totaled approximately $1.9 billion, or $2.68 per diluted common… |